Clinical Trial Update: AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of AZD2171 (cediranib) in patients with recurrent non-small cell lung cancer has completed, with results posted in October 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD2171 (cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-10-02